Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 32,717 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Oral Tablet Clear all
Terminated Phase 2Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

NCT05978063
View directory record Official record
Conditions
Pruritus, Notalgia Paresthetica
Interventions
difelikefalin 2.0 mg tablets, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets, Placebo tablets
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Levetiracetam (Keppra) on Alcohol Consumption

NCT01168687
View directory record Official record
Conditions
Alcohol Abuse, Drug Abuse
Interventions
Levetiracetam (Keppra), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT02734693
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
dasotraline 4mg, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 2, 2026, 6:31 AM EDT
Not listed Phase 3 Interventional

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

NCT04806893
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions
lerodalcibep, Placebo
Drug · Other
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)

NCT02367521
View directory record Official record
Conditions
TBI Depression
Interventions
Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS), Sham Comparator: Sham Treatment
Combination Product · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers

NCT00565214
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Group 1, Group 2
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 2, 2026, 6:31 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

NCT03008616
View directory record Official record
Conditions
Severe Preeclampsia
Interventions
AMAG-423 (digoxin immune fab), Placebo
Biological · Other
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Mobile, Alabama • Kansas City, Kansas • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

NCT00287716
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02545504
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Andecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • Whittier, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of DHA on Periodontitis

NCT01976806
View directory record Official record
Conditions
Periodontitis, Gingivitis, Inflammation
Interventions
Aspirin, Docosahexaenoic acid, Placebo (for Docosahexaenoic acid)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 2, 2026, 6:31 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Cannabis for Obesity Trial

NCT06137365
View directory record Official record
Conditions
Obesity
Interventions
Cannabis, Placebo
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

NCT03077165
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
S42909 100 mg, S42909 200 mg, S42909 400 mg, S42909 800 mg, S42909 1200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Ilkos Therapeutic Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Carmichael, California • Castro Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 2, 2026, 6:31 AM EDT
Terminated Phase 2 Interventional Results available

Adherence to Antidepressant Treatment in Subjects With Depression

NCT03388164
View directory record Official record
Conditions
Depression
Interventions
Escitalopram + RT2CK17, Escitalopram + Placebo
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 2, 2026, 6:31 AM EDT
Recruiting Phase 3 Interventional

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)

NCT04344184
View directory record Official record
Conditions
COVID-19, Lung Injury, Acute, Kidney Injury
Interventions
L-ascorbic acid, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Optimizing Pharmacotherapy for Bipolar Alcoholics

NCT00302133
View directory record Official record
Conditions
Bipolar Disorder, Alcohol Dependence
Interventions
Naltrexone hydrochloride, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

NCT05695352
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

NCT02190747
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene, Placebo
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of LY2811376 Single Doses in Healthy Subjects

NCT00838084
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2811376, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 2, 2026, 6:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study for Safety and Tolerability of AL002.

NCT03635047
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
AL002, Saline Solution
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 2, 2026, 6:31 AM EDT
Suspended Phase 2Phase 3 Interventional

Effects of 5HTP and LDOPA on CNS Excitability After SCI

NCT04000919
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
5HTP, L-DOPA, Placebo oral tablet, Carbidopa
Drug
Lead sponsor
Jessica M D'Amico
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 2, 2026, 6:31 AM EDT